PMID- 37539050 OWN - NLM STAT- MEDLINE DCOM- 20230807 LR - 20230808 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population. PG - 1197458 LID - 10.3389/fimmu.2023.1197458 [doi] LID - 1197458 AB - OBJECTIVE: Several studies have demonstrated that anti-carbamylation protein antibodies (Anti-CarPA) are persistent in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSC), primary Sjogren's syndrome (pSS), and interstitial lung disease associated with RA (RA-ILD). However, the relationship between anti-CarPA and other rheumatic diseases (RDs) and non-RA-ILD is not known till now. This study sought to examine the presence of anti-CarPA in Chinese Han patients with RDs and its clinical significance. METHODS: The study included 90 healthy controls (HCs) and 300 patients with RDs, including RA, SLE, polymyositis/dermatomyositis (PM/DM), pSS, SSC, spondyloarthritis (SpA), anti-neutrophil cytoplasmic autoantibodies associated with vasculitis (AAV), undifferentiated connective tissue disease (UCTD), and Behcet's disease (BD). Antibodies against carbamylated human serum albumin were detected using commercial enzyme-linked immunosorbent assay kits. Correlations between clinical and laboratory parameters were analyzed. RESULT: Serum levels of anti-CarPA in RA (34.43 +/- 33.34 ng/ml), SLE (21.12 +/- 22.23 ng/ml), pSS (16.32 +/- 13.54 ng/ml), PM/DM (30.85 +/- 17.34 ng/ml), SSC (23.53 +/- 10.70 ng/ml), and UCTD (28.35 +/- 21.91 ng/ml) were higher than those of anti-CarPA in the HCs (7.30 +/- 5.05 ng/ml). The concentration of serum anti-CarPA was higher in patients with rheumatic disease-related interstitial lung disease (RD-ILD), especially RA-ILD, PM/DM-ILD, and pSS-ILD. Patients with RD-ILD who tested positive for anti-CarPA were more likely to have a more severe radiographic classification (grades II, p = 0.045; grades III, p = 0.003). Binary logistic regression analysis suggested that anti-CarPA had an association with ILD in RA (p = 0.033), PM/DM (p = 0.039), and pSS (p = 0.048). Based on receiver operating characteristics (ROC) analysis, anti-CarPA cutoffs best discriminated ILD in RA (>32.59 ng/ml, p = 0.050), PM/DM (>23.46 ng/ml, p = 0.038), and pSS (>37.08 ng/ml, p = 0.040). Moreover, serum levels of anti-CarPA were correlated with antibodies against transcription intermediary factor 1 complex (anti-TIF1) (R = -0.28, p = 0.044), antibodies against glycyl-transfer ribonucleic acid synthetase (anti-EJ) (R = 0.30, p = 0.031), and antibodies against melanoma differentiation-associated gene 5 (anti-MDA5) (R = 0.35, p = 0.011). CONCLUSION: Serum anti-CarPA could be detected in patients with RA, PM/DM, pSS, SSC, and UCTD among the Chinese Han population. And it may also assist in identifying ILD in patients with RA, PM/DM, and pSS, which emphasized attention to the lung involvement in anti-CarPA-positive patients. CI - Copyright (c) 2023 Dong, Sun, Xu, Xiang, Li, Yang, Zhu and Ma. FAU - Dong, Rongrong AU - Dong R AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. FAU - Sun, Yuanyuan AU - Sun Y AD - Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Xu, Wei AU - Xu W AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. FAU - Xiang, Weizhen AU - Xiang W AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. FAU - Li, Meiqi AU - Li M AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Yang, Qingrui AU - Yang Q AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Zhu, Ling AU - Zhu L AD - Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Ma, Zhenzhen AU - Ma Z AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. AD - Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230719 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Antineutrophil Cytoplasmic) SB - IM MH - Humans MH - Clinical Relevance MH - East Asian People MH - *Dermatomyositis MH - *Rheumatic Diseases/complications MH - *Lupus Erythematosus, Systemic MH - *Arthritis, Rheumatoid MH - *Lung Diseases, Interstitial MH - *Scleroderma, Systemic MH - Antibodies, Antineutrophil Cytoplasmic PMC - PMC10394697 OTO - NOTNLM OT - Chinese patients OT - anti-carbamylation protein antibodies OT - autoantibodies OT - interstitial lung disease OT - rheumatic diseases COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/08/04 06:42 MHDA- 2023/08/07 06:42 PMCR- 2023/01/01 CRDT- 2023/08/04 04:10 PHST- 2023/03/31 00:00 [received] PHST- 2023/07/03 00:00 [accepted] PHST- 2023/08/07 06:42 [medline] PHST- 2023/08/04 06:42 [pubmed] PHST- 2023/08/04 04:10 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1197458 [doi] PST - epublish SO - Front Immunol. 2023 Jul 19;14:1197458. doi: 10.3389/fimmu.2023.1197458. eCollection 2023.